A 2-hour infusion of 0.1 to 10 mg/kg ponezumab was well tolerated in subjects with mild-to-moderate AD. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
60/100
Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study, Triflusal therapy was associated with a significant lower rate of conversion to dementia that is likely to be clinically relevant. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A plethora of reports suggest that copper (Cu) homeostasis is disturbed in Alzheimer's disease (AD). 4 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These findings do not provide evidence of improvement in behavioral symptoms, functional status, or QoL of hearing impaired AD patients and their caregivers after 6 months of HA use. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Milacemide does not appear to be an effective treatment in enhancing cognition in SDAT patients. 2 key findings →
Participants: 113 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These estimates suggest that DSS provides clinically important reductions in symptoms of AD and VD and can be a promising anti-dementia drug candidate. 5 key findings →
Design: systematic review Participants: 567 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study indicates no benefits for memantine in the long-term treatment and prophylaxis of clinically significant neuropsychiatric symptoms. 5 key findings →
Participants: 199 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
At baseline, there were no statistically significant differences in demographic characteristics and in outcome variables (HHI, GSES, and SF-12v2 mental component score and physical component score) between users and nonusers. 5 key findings →
Design: randomized controlled trial Participants: 101 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
MI failed to show an effect on metabolism in FDG-based AD biomarker, but exploratory analysis suggested positive effect on limbic system metabolism. 4 key findings →
Participants: 67 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The results of the included studies were summarized using a narrative synthesis or meta-analysis, as appropriate. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Caregiver stress is associated with negative outcomes for both caregivers and care recipients. 5 key findings →
Design: randomized controlled trial Participants: 14 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Reality orientation therapy combined with cholinesterase inhibitors has not been evaluated in patients with Alzheimer's disease. 4 key findings →
Participants: 156 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study reported the generation of aducanumab, a human monoclonal antibody designed to selectively target aggregated Aβ. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing, affecting around 46 million people worldwide but few treatments are currently available. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Current approaches to the early detection of Alzheimer's disease (AD) rely upon classifying individuals as "positive" or "negative" for biomarkers related to the core pathology of β-amyloid (Aβ). 5 key findings →
Design: longitudinal study Participants: 71 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognition-oriented treatments (COTs) are a group of non-pharmacological treatments aimed at maintaining or improving cognitive functioning. 1 key finding →
Design: systematic-review Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Memory loss is one of the first symptoms of typical Alzheimer's disease (AD), for which there are no effective therapies available. 3 key findings →
Participants: 14 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
59/100
AV45 PET scans were performed in 271 individuals and preliminary results showed that 38.0% had a cortical SUVR > 1.17, which gave an indication of significant brain amyloïd deposit. 1 key finding →
Participants: 1,680 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Eight out of 15 patients completed the entire study. 4 key findings →
Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Individuals with AD and VaD have higher Hct levels than controls; however, a causal relationship between high-Hct level and risk of developing dementia is not supported. 5 key findings →
Design: meta-analysis Participants: 6,122 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Controlling for pretest, the benefit-finding group had lower depression than the psychoeducation group at post-test, despite the fact that some caregivers found benefit-finding challenging. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Homocysteine lowering in dementia patients did not significantly reduce global cognitive decline. 3 key findings →
Participants: 140 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
1680 participants were randomized over the recruitment period in MAPT study. 1 key finding →
Participants: 1,680 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Subjects receiving the activity specific exercise program improved in ability to perform transfers, whereas subjects in the other 2 groups declined. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →